CN109456391A - A kind of VLP vaccine and its preparation method and application preventing goose astrovirus infection - Google Patents
A kind of VLP vaccine and its preparation method and application preventing goose astrovirus infection Download PDFInfo
- Publication number
- CN109456391A CN109456391A CN201811336103.XA CN201811336103A CN109456391A CN 109456391 A CN109456391 A CN 109456391A CN 201811336103 A CN201811336103 A CN 201811336103A CN 109456391 A CN109456391 A CN 109456391A
- Authority
- CN
- China
- Prior art keywords
- goose
- vaccine
- val
- ser
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/12011—Astroviridae
- C12N2770/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/12011—Astroviridae
- C12N2770/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a kind of VLP vaccines and its preparation method and application for preventing goose astrovirus infection, belong to veterinary biologics field.The present invention passes through clone, amplification Capsid albumen full genome;GoAsV/Bac plants of recombinant baculovirus of the antigen protein are expressed using insect cell-baculovirus expression system building, recombinant virus high efficient expression antigen protein in insect cell HF;Adjuvant emulsion is added after extraction purification, BEI inactivation, vaccine is made.The preparation method is simple, can largely prepare goose astrovirus Capsid albumen, and time-consuming short, expression quantity is high, substantially reduces production cost, is conducive to be mass produced.It include the goose astrovirus VLP vaccine of Capsid albumen prepared by preparation method of the present invention, immune effect is good, and immunizing dose is small, can effectively prevent the infection of goose astrovirus.
Description
Technical field
The present invention relates to a kind of VLP vaccines and its preparation method and application for preventing goose astrovirus infection, belong to for animals
Field of biological product.
Background technique
Goose astrovirus mainly causes gaggle that serious severe visceral pain wind and arthragra, and goose throughout the country occurs
There is generation in factory.According to the literature and raiser's oral account, this disease betide 2011 earliest, and Hebei province introduces France Ao Erweiya
Corporate investment creates Anser anser field, occurs as soon as gout symptom from the Anser anser seedling of Ao Er NIVEA Corp December current year, later by
Year spreads at home, and by 2016~2017 years, case all occurred in all goose kinds, all feeding goose places at home.The disease mainly exists
It falls ill on young goose, infection age in days is 2~25 ages in days, and young goose is susceptible within predominantly 15 ages in days.This disease occurs throughout the year, annual November
It is peak season to May next year, it may be with related, other time morbidity reduction of divulging information, keep the temperature.The infected age in days of case fatality rate, after
The factors such as hair infection influence, and for gaggle infection rate 80% or more, disease incidence reaches as high as 50%, which has become harm and support goose
Industry develops in a healthy way a kind of Important Infectious Diseases.
Currently, vaccine inoculation is prevention, controls and even eliminate one of mainly arranging for goose astrovirus, subunit vaccine, especially
It is viroid sample particle vaccines (Virus like particles, VLPs), and this kind of vaccine does not contain nucleic acid substances, safety
Preferably, persistent infection or latent infection will not be generated after inoculation, the immune response of generation can mutually be distinguished with wild virus infection, favorably
In the control and elimination of epidemic disease.
Therefore the good goose astrovirus subunit of a kind of low production cost, high production efficiency and immune effect of vaccine is developed
The production method of vaccine has important practical significance.
Summary of the invention
The first purpose of the invention is to provide a kind of for preventing the antigen of goose astrovirus infection, and the antigen contains
Amino acid sequence shown in SEQ ID NO.1.
In one embodiment of the invention, the amino acid sequence of the antigen is as shown in SEQ ID NO.1.
A second object of the present invention is to provide the DNA for encoding the antigen.
Third object of the present invention is to provide the compositions for containing the antigen.
In one embodiment of the invention, the antigen is inactivated by BEI.
Fourth object of the present invention is to provide goose astrovirus virus vlps vaccine, contains the antigen and vaccine adjuvant.
In one embodiment of the invention, the content of the antigen is 25~100 μ g/mL.
In one embodiment of the invention, the adjuvant is oil adjuvant.
Fifth object of the present invention is to provide the antibody that application antigen immune response obtains.
Sixth object of the present invention is to provide the antibody in terms of the drug of preparation prevention and treatment goose astrovirus infection
Using.
The pharmaceutical composition containing the antibody in conjunction with the antigentic specificity is also claimed in the present invention.
The utility model has the advantages that the present invention is by the recombinant baculovirus rBac-GoAsV- of the goose astrovirus Capsid albumen of expression
Capsid, access insect cell efficiently express Capsid albumen, remove cell fragment by centrifugation, after BEI inactivation is added, add
Enter oil adjuvant mixing and emulsifying and vaccine is made.Vaccine prepared by the present invention has the advantages that efficient, safety is good, can effective stimulus kind
Goose generates active immunity, young goose generates passive immunity, and the antibody level generated can help young goose to resist lethal dose virus
Attack.Using the young goose of vaccine immunity prepared by the present invention, after 4~5 weeks yolk GoAsV fine jade expand antibody titer average value >=
3.0log2;After the susceptible laying breeding geese 28d of immune health each group goose goose astrovirus fine jade expand antibody titer average value >=
3.6log2, passive immunity group young bird goose serum GoAsV fine jade expand antibody titer average value >=2.7log2, attack protective rate on the 14th after poison
Up to 100%.
Detailed description of the invention
Fig. 1 is the PCR amplification result figure of Capsid entire open reading frame;Wherein, M:DL5000 DNA Marker;1:
Control;2:PCR product;
Fig. 2 is transfer vector building PCR qualification result figure;Wherein, M:DL5000 DNA Marker;1~7:7 different
Bacterium colony PCR;
Fig. 3 is restructuring rod granule PCR qualification result figure;Wherein, M:DL5000 DNA Marker;1~7:7 different bacterium colony
PCR;
Fig. 4 is SDS-PAGE detection recombinant baculovirus expression product;Wherein, M: pre- dsred protein Marker;1:Sf9 is thin
Born of the same parents' culture;2: wild baculovirus infection sf9 cell;3:F3 is for recombinant baculovirus;
Fig. 5 is Western Blot identification recombinant baculovirus expression product;Wherein, M: pre- dsred protein Marker;1:
Infect the Sf9 cell of empty baculoviral;2:F3 is for recombinant baculovirus;
Fig. 6 is recombinant virus sample particle electromicroscopic photograph.
Specific embodiment
Embodiment 1: the building of recombinant baculovirus
1, goose astrovirus RNA is extracted: extracting LH plants of total serum IgEs of goose astrovirus with TRIzol Reagent kit;
2, goose astrovirus cDNA is synthesized: according to HiScript II One Step RT-PCR Kit kit (Nanjing promise
Wei Zan Biotechnology Co., Ltd, product number: P611-01) operating instruction progress cDNA synthesis.
3, design of primers and synthesis: announced according to GenBank goose astrovirus Capsid gene order (accession number:
NC_034567 a pair of of specific primer) is designed, and adds EcoR I and Xho I restriction enzyme site respectively at primer both ends, it is amplifiable
The target fragment of 2124bp out.Primer sequence is respectively as follows:
P1:CCGGAATTCATGGCCGACAAGGTCACTGTCTCAG
P2:CCGCTCGAGTTAATCAAACTCTTGTCCGCCCTTC
4, Capsid gene fragment amplification and recycling
(1) PCR amplification: using the DNA of extraction as template, the primer in step 2 is PCR.PCR reaction system is (total volume
25 μ L): 0.5 μ L of DNA profiling, P1 and P2 11 μ L of 0.5 μ L, 12.5 μ L of archaeal dna polymerase and sterile water.PCR reaction condition are as follows: 95
DEG C, 5min;95 DEG C of 30s, 65 DEG C of 30s, 72 DEG C of 120s, 30 circulations;72℃10min.1% agarose gel electrophoresis shows, at
Function amplifies the specific band of about 2124bp, is consistent (Fig. 1) with expected size.
(2) target fragment glue recycles: by PCR product through 1% agarose gel electrophoresis, gel extraction purpose in the UV lamp
Segment.Concrete operations are carried out referring to plastic recovery kit specification.
4, target gene and transfer plasmid connect: by pFastBac I and capsid gene amplification fragment with EcoR I and
It is separately recovered, purifies after Xho I digestion, overnight with 4 DEG C of T4DNA ligase connections.
5, connection product transformed competence colibacillus cell: connection product is aseptically converted in T1 competent cell, is mixed
Even, 800uL LB culture is added based on 37 DEG C of concussions under aseptic condition in ice bath 30min, 42 DEG C of heat shock 90s, immediately ice bath 2min
Cultivate 60min.Culture 14000rpm is centrifuged 1min, 800uL supernatant is drawn, remaining culture is coated on LB (benzyl containing ammonia
Penicillin resistance) in solid medium, 37 DEG C are incubated overnight.Picking single colonie makees bacterium colony PCR identification, positive plasmid inspection sequencing
(Fig. 2).Correct recombinant plasmid is sequenced and is named as pFastBac I-GoAsV-capsid.
6, recombinant baculovirus constructs: will identify that correct transfer plasmid pFastBac I-GoAsV-capsid is transferred to greatly
In enterobacteria DH10Bac competent cell, selects positive colony M13 primer and make PCR identification.
M13-F:TGTAAAACGACGGCCAGT
M13-R:CAGGAAACAGCTATGAC
PCR reaction system is (25 μ L of total volume): 0.5 μ L of DNA profiling, M13-F and M13-R 0.5 μ L, archaeal dna polymerase
11 μ L of 12.5 μ L and sterile water.PCR reaction condition are as follows: 93 DEG C, 5min;94 DEG C of 30s, 55 DEG C of 45s, 72 DEG C of 5min, 30 circulations;
72℃10min.1% agarose gel electrophoresis shows that Successful amplification goes out the specific band of about 4500bp, is consistent with expected size
(Fig. 3).Positive restructuring rod granule is named as rBacmid-GoAsV-capsid.
7, restructuring rod granule transfects sf9 cell: the method for the restructuring rod granule liposome transfection of purification is turned restructuring rod granule
Sf9 cell is contaminated, concrete operation method is said referring to the cellfectin transfection reagent of silent your scientific and technological (China) Co., Ltd of winged generation of match
Bright book carries out, and obtains f1 for recombinant baculovirus rBac-GoAsV-capsid.
Embodiment 2: the preparation of recombinant C apsid albumen
1, recombinant baculovirus expand: by recombinant baculovirus rBac-GoAsV-capsid be inoculated with sf9 insect cell, 27
DEG C culture 4 days, collect culture, centrifuging and taking supernatant i.e. obtain f2 for recombinant baculovirus;
2, Identification of Fusion Protein is expressed:
(1) above-mentioned f2 is accessed into sf9 insect cell, 27 DEG C of cultures for recombinant baculovirus with the inoculum concentration of MOI=5~10
4 days, culture is collected, centrifuging and taking supernatant obtains recombinant C apsid albumen;
(2) SDS-PAGE is identified: above-mentioned supernatant is carried out SDS-PAGE electrophoresis;After electrophoresis, is dyed and decolourized
After find, about in the position 80kDa, molecular weight is consistent with theoretical size, illustrates to express successfully (Fig. 4), through being sequenced, the albumen
Amino acid sequence as shown in SEQ ID NO.1.
(2) Western Blot is identified: being taken gel after SDS-PAGE electrophoresis, is directly used BIO-LAB transfer device by its turn
It prints on NC film, after transfer, carries out Western blot identification according to a conventional method.It is referred to goose astrovirus positive serum
Product (1:200) are used as primary antibody;Use the rabbit-anti goose IgG (1:2000) of horseradish peroxidase-labeled as ELIAS secondary antibody;Finally use
TMB develops the color (green skies biotechnology research institute).The result shows that occur 1 apparent specific band at 80kDa, and it is negative
Property control without this specific reaction, illustrate that the recombinant protein can identify by the antibody in goose astrovirus positive serum, with good
Good specificity and reactionogenicity (Fig. 5).
10, the great expression of recombinant C apsid albumen: it will identify that correct recombinant virus connects malicious amount with MOI=1~10
It is inoculated with HF cell mass propgation, culture solution supernatant is collected by centrifugation, that is, obtains and contains a large amount of recombinant C apsid albumen, by expression
Recombinant C apsid albumen carries out Electronic Speculum detection (Fig. 6).
Embodiment 3: vaccine preparation
1, it inactivates: the recombinant C apsid albumen largely prepared in embodiment 2 being added in inactivation tank, is added final concentration of
0.2%~0.5% inactivator BEI, for 24 hours in 37 DEG C of inactivations.
2, the inspection of semifinished product
(1) steriling test: steriling test is carried out by existing " Chinese veterinary pharmacopoeia " annex.
(2) determining the protein quantity: protein content is detected by BCA method.
(3) inactivation is examined: the protein liquid after inactivation being taken sf9 insect cell, 27 DEG C is placed in and continues culture 72 hours.Observation
No lesion occurs, and it is qualified to determine that inactivation is examined.
3, VLP vaccine preparation:
Carrying out vaccine preparation by semi-finished product proteantigen after the assay was approved, (each liquid component presses volume in following preparation
Than meter).
(1) oil is mutually prepared: 95 parts of white oil for animals are taken, 1 part of aluminum stearate, is placed in oily phase preparation tank after being heated to 80 DEG C,
Again plus 5 parts of Si Ben -80, it until when temperature reaches 115 DEG C, maintains, it is spare after cooling.
(2) recombinant protein is used normal saline dilution at 50 μ g/mL by water phase preparation.5 parts of Tween-80s after taking sterilizing,
It is added in Agitation Tank, while being added 95 parts of seedling protein liquid, stir 20~30min, be completely dissolved Tween-80.
(3) emulsification takes 2 parts of oily phase to be put in high-speed shearing machine, starts the stirring of motor slow rotation, while water being added slowly
1 part of phase, with 10000rpm emulsification 5 minutes.After emulsification, 10mL is taken, 15min is centrifuged with 3000rpm, the water phase that tube bottom is precipitated should not
More than 0.5mL.
, embodiment 4: vaccine product inspection
1, character
Appearance: vaccine should be milky Virgin's milk agent, free from admixture and qualification is answered in outer packing;
Dosage form: water-in-oil type.A cleaning suction pipe is taken, a small amount of vaccine is drawn and instills in cold water, in addition to the first drop, should all not be expanded
It dissipates.
Stability: drawing vaccine 10mL and be added in centrifuge tube, is centrifuged 15min with 3000rpm, water phase Ying Buchao is precipitated in tube bottom
Cross 0.5mL.
Viscosity: it is carried out by existing " Chinese veterinary pharmacopoeia " annex, regulation should be met.
2, it loading quantity inspection: is carried out by existing " Chinese veterinary pharmacopoeia " annex, regulation should be met.
3, it steriling test: is carried out by existing " Chinese veterinary pharmacopoeia " annex, regulation should be met.
4, safety verification:
Goose astrovirus VLP vaccine is prepared as described in Example 3, and lot number is respectively rCapsid-001P, rCapsid-
002P, rCapsid-003P totally 3 batches.3~5 age in days young bird geese, 1 monthly age goose, 7 monthly ages that goose astrovirus fine jade expands negative antibody open production
Kind goose, September age laying breeding geese.Every batch of vaccine chooses 3~5 age in days young bird geese 10 respectively, 1 monthly age goose 10,7 monthly ages open a production kind goose
10, September age laying breeding geese 10, every chest muscle of young goose inject 0.2mL, and every chest muscle of remaining goose vaccinates
1.0mL, every group of goose for separately taking 10 identical sources, identical age in days, as nonimmune control group.21 are observed continuously after injection
Day, daily situations such as observing each group goose mental status, drinking-water, food-intake;7 days after immune, 14 days, touchs on the 21st check each be immunized
Whether group goose injection site has the reaction of the locally injectings such as redness;It weighs before immune with after being immunized 21;Laying breeding geese statistics is laid eggs
Situation appoints 20 pieces of the produced goose embryo of kind goose on the 21st after taking every batch of vaccine immunity respectively, marks, whether compare goose embryo hatching rate
It is variant;It cuts open and kills all geese, check injection site vaccine absorbing state, whether have pathological change;10 young birds of every group of random screening
Raising is to 1 monthly age after goose weighing, counts survival rate and opposite daily gain, relative immunity group and control group young bird goose survival rate and average
The difference of opposite daily gain.
5, efficacy test:
(1) it is grouped and immune
It chooses August age health and opens production kind goose 80 (goose astrovirus fine jade expands negative antibody), be randomly divided into 4 groups, every group 20
Only.Optional three groups are immunized rCapsid-001P, rCapsid-002P, rCapsid-003P batch vaccine, chest muscle note respectively
Penetrate 1mL/ only, remaining one group is nonimmune control group, and each experimental group goose marks respectively.
(2) goose serum, Yolk antibody detection are planted
Weekly by only taking a blood sample to after being immunized 28 after each experimental group goose is immune, serum is separated, detection GoAsV fine jade expands antibody;
Appoint respectively for every group and take immune latter 4~5 weeks interior 10 pieces of produced goose eggs of kind of goose (together with control group), it is anti-to detect GoAsV fine jade expansion in yolk
Body.
Respectively by three batches of vaccines with 1mL/ dose immunization, the susceptible laying breeding geese of immune health, the goose star of each group goose after 28d
Shape virus fine jade expand antibody titer average value >=3.6log2, the antibody of nonimmune control group is feminine gender, and concrete outcome is shown in Table 1.
Serum GoAsV fine jade expands antibody after a kind of goose of table is 28 days immune
The detection of goose egg Yolk antibody:
Appoint in 4~5 weeks after every batch of vaccine immunity group is immune and take 10 pieces of goose eggs, it is flat that yolk GoAsV fine jade expands antibody titer
Mean value >=3.0log2, it is feminine gender that 10 pieces of goose egg yolk GoAsV fine jades of nonimmune control group, which expand antibody, the results are shown in Table 2.
Goose egg yolk GoAsV fine jade expands antibody titer in 4~5 weeks after table 2 is immune
(3) 3 age in days young bird goose passive immunity challenge viral dosages
Every experimental group is appointed respectively takes immune latter 4~5 weeks interior 30 pieces of produced hatching eggs (together with control group), marks, sets 38
DEG C incubator is hatched 29~30, the young goose that immune group is hatched optional 20, control group 20, is put on footnote, is placed in and attacks poison
It is raised in area's isolator 3, every group of young bird goose blood sampling separation serum, detection GoAsV fine jade expands antibody.Carry out challenge viral dosage simultaneously:
GoAsV attacks malicious group, attacks malicious (every milliliter of allantoic fluid viral level 10 with GoAsV-LH plants of F3 generations4.03ELD50/ 0.2mL), every young bird
Goose takes orally 0.5mL, and 0.5mL is subcutaneously injected in neck, attacks poison 10;Immune group and control group are individually insulated breeding observing 14, remember
Record morbidity, dead and protection situation.
The results show that the 3 batches of vaccine passive immunity groups every group 10 young goose serum GoAsV fine jades expand antibody titer average values >=
2.7log2 the results are shown in Table 3.
33 age in days young bird goose passive immunizing agent GoAsV fine jade of table expands antibody titer
(4) 3 age in days young bird goose passive immunity challenge viral dosages:
3 batches of vaccine passive immunity group every group 10 young geese search for food after attacking poison, drink water, the state of mind is normal, and no goose is starlike
Viral clinical symptoms occur, and attack every group of equal 10/10 strong work on the 14th after poison.Non-passive immunized controls group young bird goose attacks essence on the 3rd after poison
Mind starts to occur that spirit is depressed, anorexia, astasia, peels off, and arranges dilute canescence or yellow green excrement, attacks the 5th day after poison and occur
Death, until attacking total dead 5 young geese on the 10th after poison.Every goose dissect of dying of illness, plantar, instep, toe joint enlargement subcutaneously have a large amount of uric acid
Salt;There is lime sample uric acid mineralization in entire heart and partial liver;Kidney enlargement, hyperemia, surface are covered with lime sample lithate
Deposition;Lungs surface distribution table hydrochlorate deposition;Glandular stomach spreads uric acid mineralization;Spleen bleeding is serious, there is canescence necrosis region etc..
Passive immunity, which attacks poison protection, the results are shown in Table 4.
43 age in days young bird goose passive immunity of table attacks malicious (LH plants of goose astrovirus)
The above results show that 3 batch vaccines have good immune effect to kind of goose, make to contain in serum when young goose hatching
The GoAsV antibody of higher level can effectively resist the attack of goose astrovirus.
Although the present invention has been described by way of example and in terms of the preferred embodiments, it is not intended to limit the invention, any to be familiar with this skill
The people of art can do various change and modification, therefore protection model of the invention without departing from the spirit and scope of the present invention
Enclosing subject to the definition of the claims.
SEQUENCE LISTING
<110>Yangzhou You Bang biologics Co., Ltd
<120>a kind of VLP vaccine and its preparation method and application for preventing goose astrovirus infection
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 504
<212> PRT
<213>GoAsV LH plants of Capsid protein amino acid sequences
<400> 1
Met Ala Asp Lys Val Thr Val Ser Val Lys Lys Ala Lys Ala Arg Gly
1 5 10 15
Arg Thr Arg Ser Arg Ser Arg Ser Arg Ser Arg Ser Arg Ser Arg Gly
20 25 30
Lys Arg Val Ile Ile Lys Lys Lys Lys Ala Lys Thr Ile Lys Lys Lys
35 40 45
Arg Lys Lys Arg Val Arg Lys Val Arg Arg Ile Lys Gly Arg Val Ser
50 55 60
Asp Thr Lys Thr Thr Val Thr Gly Arg Val Gly Asn Asp Asp Ser Ser
65 70 75 80
Arg Lys Val Asn Thr Met Lys Asn Asp Ala Gly Ser Ala Ser Ser Thr
85 90 95
Ile Arg Ala Ser Tyr Gly Trp Arg Ile Val Cys Val Arg Thr Ala Gly
100 105 110
Ala Ala Asn Val Gly Thr Val Val Ala Asp Ser Gly Val Ala Thr Ala
115 120 125
Ser Asp Thr Ile Lys Ala Arg His Val Ser Val Gly Met Arg Tyr Val
130 135 140
Trp Lys Ile Lys Arg Gly Arg Gly Trp Trp Asn Met Asp Thr Gly Asp
145 150 155 160
Asp Thr Asn Ser Gly Ala Ile Ser Trp Thr Tyr Arg Thr Val Ala Ser
165 170 175
Ser Thr Asn Ser Val Gly Gly Ile Val Ala Asn Val Arg Tyr Ser Asn
180 185 190
Tyr Thr Lys Asn Ala Met Asn Arg Ile Thr Val Lys Ser Gly Ile Thr
195 200 205
Lys Asn Asp Thr Asp Gly Ser Val Val Met Val Asp Ala Arg Ala Ile
210 215 220
Asp Asn Arg Arg Thr Asn Ala Ser Gly Gly Lys Trp Ala Val Ser Thr
225 230 235 240
Thr Val Val Asp Val Val Ala Asp Ala Ile Gly Trp Gly Trp Lys Gly
245 250 255
Gly Trp Trp Val Ile Arg Lys Ile Gly Ala Ala Gly Asn Ala Ser Lys
260 265 270
Tyr Ala Ile Tyr Ala Ser Val Asp Ala Lys Asn Asn Ser Lys Ile Val
275 280 285
Lys Ser Ile Ser Asn Arg Val Ile Thr Ile Asn Val Asn Ser Gly Ile
290 295 300
Ala Thr Thr Gly Gly Ala Ala Val Ala Ile Tyr Arg Ile Ala Asn Asn
305 310 315 320
Ile Tyr Asp Val Asp Arg Val Asp Gly Asp Trp Tyr Cys Asn Asn Gly
325 330 335
Ile Ala Thr Thr Val Thr Ala Ser Ser Ala Met Gly Thr Ala Asn Val
340 345 350
Arg Thr Arg Thr Asn Trp Val Asp Tyr Ser Asp Asn Gly Val Ser Thr
355 360 365
His Thr Gly Val Thr Thr Ala Ala Asn Ile Trp Ser Ser Ser Arg Thr
370 375 380
His Ala Thr Ser Cys Asp Gly Thr Arg Thr Gly Ile Ser Asn Asp Val
385 390 395 400
Lys Gly Val Trp Ser Thr Asn Asn Ala Ser Gly Ser Val Ile Asn Asn
405 410 415
Asn Met Gly Trp Val Val Ser Lys His Lys Val Arg Val Tyr Trp Thr
420 425 430
Gly Ser Asn Asp Tyr Ile Val Trp Val Lys Ser Val Ser Ala Tyr Met
435 440 445
Gly Ser Trp Asn Asn Asn Tyr Arg Arg Ala Asp Asp Ile Asp Met Ser
450 455 460
Ile Thr Ile Lys Ser Arg Asp Thr Asp Ser Lys Cys Ser Lys Thr Ser
465 470 475 480
Asp Ala Arg Ala Tyr Trp Arg Ala Lys Ala Ala Lys Ala Met Ser Ala
485 490 495
Thr Gly Val Arg Lys Gly Gly Asp
500
<210> 2
<211> 34
<212> DNA
<213>artificial sequence
<400> 2
ccggaattca tggccgacaa ggtcactgtc tcag 34
<210> 3
<211> 34
<212> DNA
<213>artificial sequence
<400> 3
ccgctcgagt taatcaaact cttgtccgcc cttc 34
<210> 4
<211> 18
<212> DNA
<213>artificial sequence
<400> 4
tgtaaaacga cggccagt 18
<210> 5
<211> 17
<212> DNA
<213>artificial sequence
<400> 5
caggaaacag ctatgac 17
Claims (10)
1. a kind of antigen, which is characterized in that contain amino acid sequence shown in SEQ ID NO.1.
2. encoding the DNA molecular of antigen described in claim 1.
3. the composition containing antigen described in claim 1.
4. composition according to claim 3, it is characterised in that antigen is inactivated by BEI.
5. a kind of vaccine for preventing and treating goose astrovirus VLP, which is characterized in that helped containing antigen described in claim 1 and vaccine
Agent.
6. vaccine according to claim 5, which is characterized in that the content of the antigen is 25~100 μ g/mL.
7. vaccine according to claim 5 or 6, which is characterized in that the adjuvant is oil adjuvant.
8. the immune antibody obtained of antigen described in application claim 1.
9. application of the antibody as claimed in claim 9 in terms of the drug of preparation prevention and treatment goose astrovirus infection.
10. the pharmaceutical composition containing antibody described in claim 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811336103.XA CN109456391B (en) | 2018-11-12 | 2018-11-12 | A kind of VLP vaccine and its preparation method and application preventing goose astrovirus infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811336103.XA CN109456391B (en) | 2018-11-12 | 2018-11-12 | A kind of VLP vaccine and its preparation method and application preventing goose astrovirus infection |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109456391A true CN109456391A (en) | 2019-03-12 |
CN109456391B CN109456391B (en) | 2019-09-03 |
Family
ID=65609982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811336103.XA Active CN109456391B (en) | 2018-11-12 | 2018-11-12 | A kind of VLP vaccine and its preparation method and application preventing goose astrovirus infection |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109456391B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110124023A (en) * | 2019-06-03 | 2019-08-16 | 苏州世诺生物技术有限公司 | Goose astrovirus virus-like particle novel gene engineering subunit vaccine |
CN111471701A (en) * | 2020-04-27 | 2020-07-31 | 浙江鼎持生物制品有限公司 | Method for efficiently expressing ORF2 gene of goose star virus soluble capsid protein and application thereof |
CN114457115A (en) * | 2022-03-08 | 2022-05-10 | 扬州大学 | Construction method of recombinant baculovirus expressing novel goose star virus capsid protein ORF2 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108558995A (en) * | 2018-05-22 | 2018-09-21 | 山东农业大学 | A kind of Yolk antibody and preparation method thereof of the novel goose astrovirus of prevention |
CN108567974A (en) * | 2018-05-22 | 2018-09-25 | 山东农业大学 | A kind of inactivated vaccine and preparation method thereof of the novel goose astrovirus of prevention |
-
2018
- 2018-11-12 CN CN201811336103.XA patent/CN109456391B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108558995A (en) * | 2018-05-22 | 2018-09-21 | 山东农业大学 | A kind of Yolk antibody and preparation method thereof of the novel goose astrovirus of prevention |
CN108567974A (en) * | 2018-05-22 | 2018-09-25 | 山东农业大学 | A kind of inactivated vaccine and preparation method thereof of the novel goose astrovirus of prevention |
Non-Patent Citations (1)
Title |
---|
ZHANG,Y等: "YP_009362295", 《GENBANK》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110124023A (en) * | 2019-06-03 | 2019-08-16 | 苏州世诺生物技术有限公司 | Goose astrovirus virus-like particle novel gene engineering subunit vaccine |
CN111471701A (en) * | 2020-04-27 | 2020-07-31 | 浙江鼎持生物制品有限公司 | Method for efficiently expressing ORF2 gene of goose star virus soluble capsid protein and application thereof |
CN111471701B (en) * | 2020-04-27 | 2021-12-10 | 浙江鼎持生物制品有限公司 | Method for efficiently expressing ORF2 gene of goose star virus soluble capsid protein and application thereof |
CN114457115A (en) * | 2022-03-08 | 2022-05-10 | 扬州大学 | Construction method of recombinant baculovirus expressing novel goose star virus capsid protein ORF2 |
Also Published As
Publication number | Publication date |
---|---|
CN109456391B (en) | 2019-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109456391B (en) | A kind of VLP vaccine and its preparation method and application preventing goose astrovirus infection | |
CN107551267A (en) | A kind of Goose Parvovirus subunit vaccine and its preparation method and application | |
CN108558989B (en) | 4 type aviadenovirus subunit vaccines of a kind of prevention and its preparation method and application | |
CN108558995B (en) | Yolk antibody for preventing and treating novel goose astrovirus and preparation method thereof | |
CN110872578B (en) | Variant infectious bursal disease virus, subunit vaccine, preparation method and application thereof | |
CN108653724A (en) | It is a kind of for prevent fowl egg drop syndrome vaccine composition, and its preparation method and application | |
CN105985966A (en) | Gene VII-type newcastle disease virus strain, vaccine composition thereof and preparing method and application of vaccine composition | |
CN108912227B (en) | Yolk antibody for resisting duck reovirus as well as preparation method and application thereof | |
CN105949307B (en) | It is a kind of for preventing and treating a kind Yolk antibody for duck source gosling plague | |
CN108653725A (en) | It is a kind of for prevent fowl egg drop syndrome vaccine composition, and its preparation method and application | |
CN113491767A (en) | Triple inactivated vaccine for duck circovirus disease, novel duck reovirus disease and duck viral hepatitis and preparation method thereof | |
CN114561366B (en) | Goat kuraria virus isolate and application thereof | |
CN110680914B (en) | Triple inactivated vaccine and preparation method thereof | |
CN108913666B (en) | Duck reovirus causing duck spleen necrosis and inactivated vaccine and application thereof | |
CN108676092B (en) | Egg yolk antibody for preventing and treating novel duck reovirus and preparation method thereof | |
CN106967691A (en) | A kind of recombinant rabies virus for carrying IL-6 gene and its application | |
EP2034012B1 (en) | Vaccine against viral rabbit hemorrhagic disease | |
CN108465107A (en) | A kind of 2 type adenovirus of duck and Muscovy duck parvovirus disease bivalent inactivated vaccine | |
CN106310247B (en) | The preparation method of gosling plague inactivated vaccine and its inactivated vaccine of preparation | |
CN104130981A (en) | Application of avian infectious bronchitis virus vaccine strain in preparation of inactivated vaccine | |
CN106854647A (en) | Duck virus hepatitis divalence yolk antibody and its preparation method and application | |
CN105802918B (en) | Chicken's infectious bronchitis nephritis strain and its vaccine composition, preparation method and application | |
CN109762062A (en) | A kind of preparation method of goose goat Yolk antibody | |
CN109207437B (en) | Group I8 avian adenovirus strain and application thereof | |
CN107365382B (en) | Egg yolk antibody of duck adenovirus type 2 and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |